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Prevention of doxorubicin-induced
Cardiotoxicity by pharmacological non-
hypoxic myocardial preconditioning based
on Docosahexaenoic Acid (DHA) and
carvedilol direct antioxidant effects: study
protocol for a pilot, randomized, double-
blind, controlled trial (CarDHA trial)
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Cristobal Ramos4, Daniel Hasson4, Camilo G. Sotomayor5, Pablo Henriquez3, Ignacio Cortés3, Marcia Erazo6,
Claudio Salas7 and Juan G. Gormaz7*
Abstract
Background: Anthracycline-induced cardiotoxicity (AIC), a condition associated with multiple mechanisms of
damage, including oxidative stress, has been associated with poor clinical outcomes. Carvedilol, a β-blocker with
unique antioxidant properties, emerged as a strategy to prevent AIC, but recent trials question its effectiveness.
Some evidence suggests that the antioxidant, not the β-blocker effect, could prevent related cardiotoxicity.
However, carvedilol’s antioxidant effects are probably not enough to prevent cardiotoxicity manifestations in certain
cases. We hypothesize that breast cancer patients taking carvedilol as well as a non-hypoxic myocardial
preconditioning based on docosahexaenoic acid (DHA), an enhancer of cardiac endogenous antioxidant capacity,
will develop less subclinical cardiotoxicity manifestations than patients randomized to double placebo.
Methods/design: We designed a pilot, randomized controlled, two-arm clinical trial with 32 patients to evaluate
the effects of non-hypoxic cardiac preconditioning (DHA) plus carvedilol on subclinical cardiotoxicity in breast
cancer patients undergoing anthracycline treatment. The trial includes four co-primary endpoints: changes in left
ventricular ejection fraction (LVEF) determined by cardiac magnetic resonance (CMR); changes in global longitudinal
strain (GLS) determined by two-dimensional echocardiography (ECHO); elevation in serum biomarkers (hs-cTnT and
NT-ProBNP); and one electrocardiographic variable (QTc interval). Secondary endpoints include other imaging,
biomarkers and the occurrence of major adverse cardiac events during follow-up. The enrollment and follow-up for
clinical outcomes is ongoing.
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Discussion: We expect a group of anthracycline-treated breast cancer patients exposed to carvedilol and non-
hypoxic myocardial preconditioning with DHA to show less subclinical cardiotoxicity manifestations than a
comparable group exposed to placebo.
Trial registration: ISRCTN registry, ID: ISRCTN69560410. Registered on 8 June 2016.
Keywords: CarDHA, Chemotherapy-induced cardiotoxicity, Anthracyclines, Carvedilol, DHA, Study protocol
Background
Owing to improvements in antineoplastic treatments,
overall cancer survival has improved substantially [1].
Nevertheless, these improvements have been associated
with increased incidence of chemotherapy-related side
effects. Anthracycline-induced cardiotoxicity (AIC) is a
major cause of cancer survivor morbidity and mortality
[2–4], particularly when patients develop heart failure
(HF) [5]. AIC-induced HF outcomes are worse than
other forms of HF and response to conventional therapy
can be lower, especially in cases of late detection [6],
with a 2-year mortality rate of up to 50% [7]. This con-
trasts with positive cancer therapy results where, for ex-
ample, breast cancer mortality has dropped to sit near
10% today [8, 9].
As AIC has been historically associated with left ven-
tricular systolic dysfunction (LVSD), the incidence of
AIC has been mainly expressed as a decline in different
quantitative left ventricular ejection fraction (LVEF) cri-
teria [3, 10]. AIC-induced clinical LVSD incidence
ranges around 9%, where 98% of cases develop during
the first 12 months (median time 3.5 months) [6], and
subclinical manifestations can reach 27% in 5 years [11].
However, this does not mean that AIC is not associated
with other pathological manifestations, such as arrhyth-
mias and biomarker elevation, where incidents of > 12%
and 30–35% have been reported, respectively [12].
Evidence has shown that mitochondrial-generated re-
active oxygen species (ROS) have a key role in the devel-
opment and progression of AIC [13–17]. Doxorubicin
tends to accumulate in cardiac mitochondria [18]. Inhib-
ition of the enzyme topoisomerase 2β (Top2β) by doxo-
rubicin would be the initiating event of mitochondrial
dysfunction with the subsequent generation of ROS,
promoting apoptosis and cardiac remodeling, key events
in the development of AIC [14, 19].
The role of oxidative stress in AIC has encouraged the
evaluation of several direct antioxidant strategies, with-
out satisfactory results except in the case of carvedilol
[20]. This β-blocker has uncommon ROS-suppressive
properties [21], showing mixed results in trials [22–26]
and observational studies [27]. Recently, a clinical trial
with carvedilol in 200 patients (CECCY trial) failed to
prevent a ≥ 10% reduction in LVEF at 6 months [26].
Nevertheless, the carvedilol group showed a reduction in
the increments and peak levels of serum troponin I
(TnI), trends towards a lesser increase in left ventricular
diastolic diameter and a reduction in the percentage of
patients with diastolic dysfunction.
Although β-blocker action cannot be ruled out as play-
ing a role in AIC prevention, the cardioprotective effect
from carvedilol is reported to be caused by its antioxi-
dant properties [28–31]. A recent meta-analysis, de-
signed to evaluate efficacy of β-blockers for primary
prevention of anthracycline-derived LVSD, also sug-
gested that the antioxidant properties of certain β-
blockers could explain the efficacy observed in some tri-
als [32]. As traditional orally administered ROS scaven-
gers have failed to prevent AIC [20], it can be
hypothesized that carvedilol advantages in AIC preven-
tion over other potential orally administered antioxi-
dants, may be due to carvedilol’s capacity to reach
higher concentrations in cardiac cells [30].
Different factors could explain the variability of carve-
dilol efficacy in studies. At a mechanistic level, if the car-
dioprotection was hypothetically given only due to an
antioxidant non-specific mechanism [33], a greater indi-
vidual variability response could be expected than if the
effect were a product of a specific β-blocking interaction.
At a methodological level, study weaknesses, such as
being observational, open-labeled, single-blind, combin-
ing cardiovascular drugs, or having a small sample size
probably favored mixed results [26, 34]. High heterogen-
eity of studies with regard to an accumulated dose of
anthracycline, cardiovascular risk factor profile, chemo-
therapy protocols and the involved population, as well as
a high individual variability in anthracycline bioavailabil-
ity and metabolism [35–37] can also be involved. The
use of LVSD event based on echocardiographic consen-
sus criterion (post-chemotherapy LVEF decline ≥ 10% to
< 50%) as an AIC event to define the primary endpoint,
could also be related with inconsistency in results. As
several of the latter factors determine AIC incidences,
they could partly explain different carvedilol efficacies
among protocols, because it is expected that populations
with higher AIC incidences have been more prone to
benefit from cardioprotection. For example, the CECCY
trial, despite its robustness, presented two methodo-
logical aspects that together make it difficult to appreci-
ate carvedilol-induced LVSD attenuation: (1) having
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defined a cardiotoxicity event as a decline in LVEF ≥
10% through the use of echocardiography (ECHO); and
(2) having an event incidence lower than the originally
estimated. The use of cardiac magnetic resonance
(CMR) instead of ECHO plus a redefinition of the cardi-
otoxicity event to a drop of less than 10% of the LVEF
probably would have allowed CECCY trial to appreciate
carvedilol effects at cardiac function level.
Substances with indirect antioxidant properties, both
by reducing cellular ROS production (such as iron chela-
tors) and by increasing endogenous antioxidant capacity
(such as cardiac preconditioning), are an option to be
assessed for primary AIC prevention. However, owing to
the nature of the mechanisms involved, these therapies
are not exempt of risk. Dexrazoxane, an iron chelator
has shown cardioprotective effects [38], nevertheless, it
may cause myelosuppression and potential inhibition of
doxorubicin antineoplastic efficacy [39–41]. Cardiac is-
chemic preconditioning has a broad preclinical base in
cardiology, but it is usually complex to implement in
cancer patients and its efficacy would likely be limited.
To our knowledge, currently only one study is evaluating
this type of strategy in AIC prevention [42].
Exercise as cardiac non-ischemic preconditioning has
been proposed [43–45], but due to practical complexities
for cancer patients, it is currently being tested in only
one clinical trial with a suitable population [46]. Drug-
based non-ischemic preconditioning has not been previ-
ously reported in AIC prevention clinical trials. A poten-
tial benefit of these interventions has been suggested by
Serini et al., hypothesizing that omega-3 long-chain
polyunsaturated fatty acids (EPA and DHA) could serve
as cardio-protectors [47]. Cumulative evidence is not
conclusive regarding the efficacy of EPA and DHA in
primary, secondary and tertiary cardiovascular preven-
tion [48, 49]. However, certain short-term interventions
using high DHA doses reported attenuation of post-
operative atrial fibrillation [50–52]. These effects would
not be associated to omega-3 classical anti-inflammatory
and antiplatelet mechanisms [53, 54], instead being
based on indirect antioxidant properties [55]. Integration
of DHA into cardiomyocytes induces a moderate peroxi-
dation, weak to cause harm, though enough to activate
the ROS-sensitive transcription factor Nrf2 which up-
regulates antioxidant enzymes (non-hypoxic myocardial
preconditioning) [56, 57]. Preclinical studies also re-
ported the ability of n-3 long-chain fatty acids to prevent
doxorubicin-induced ROS production and subsequent
mitochondrial damage [57, 58].
Clinical evidence has reported DHA to be safe in
metastatic breast cancer patients treated with doxorubi-
cin [59]. Additionally, we performed a three-arm pilot
protocol in patients with localized breast cancer, treated
with adjuvant doxorubicin: one group with a DHA-
enriched formula; another with carvedilol; and a double
placebo group. Eleven patients were exposed to 2 g per
day of EPA +DHA from 7 days before to 7 days after
the initial chemotherapy cycle, without showing any side
effects associated with the formula [60]. The DHA-
enriched formula inhibited NT-proB-type natriuretic
peptide (NT-ProBNP) plasmatic elevation after doxo-
rubicin chemotherapy (48 h), suggesting a subclinical
cardiotoxicity attenuation and showed a trend towards a
lower LVEF decline at 10–12months when compared to
the placebo group. The lack of statistical significance
was probably due to the small sample size and the limi-
tations associated with echocardiographic sensitivity.
The eleven patients exposed to 12.5 mg carvedilol every
12 h showed a significant reduction in LVEF drop at
10–12months (51% less drop), compared to the placebo
group. Unexpectedly, in this study arm, carvedilol did
not impact the levels of NT-ProBNP. The study popula-
tion was older and had at least one major cardiotoxicity
risk factor.
In the present study, we hypothesized that breast can-
cer patients treated with anthracycline, preconditioned
with DHA and carvedilol a week before the first chemo-
therapy cycle and for 90 days afterwards, will have less
subclinical AIC, compared to comparable patients ex-
posed to double placebo. We consider as subclinical AIC
any manifestation of cardiac injury, such as: decrease of
left ventricular function by a drop of LVEF by CMR, a
decline in global longitudinal strain by two-dimensional




CarDHA (Carvedilol-DHA trial) is a small, academic,
randomized, double-blind, placebo-controlled, two-arm
clinical trial created to test the utility of a non-hypoxic
cardiac preconditioning intervention and carvedilol to
prevent or attenuate subclinical manifestations of AIC.
It is supported by the Chilean National Commission
for Scientific and Technological Research (CONICYT)
and Clínica Alemana de Santiago. The study was initi-
ated at San Juan de Dios Hospital in Santiago. Trial
organization, management, data collection and analysis
will be coordinated with clinical study staff at both
centers. The co-authors have analyzed the study and
agreed on this manuscript.
Study population – patient selection and eligibility
criteria
This study includes patients aged 18 to 75 years with lo-
calized breast cancer receiving chemotherapy at the on-
cology unit of San Juan de Dios Hospital. Specifically,
patients with adjuvant and/or neoadjuvant systemic
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treatment with anthracycline-containing chemotherapy
are included. At stages 1 and 2, verification by physical
examination to exclude suspicion of metastasis is re-
quired. At stage 3, mammography/ultrasound or clinical
examination via imaging staging with whole-body posi-
tron emission tomography- computed tomography
(PET-CT) or abdominal thorax and pelvis CT with a
bone scintigraphy is also required. Selection is open to
all patients at the hospital who wish to participate and
meet the eligibility criteria.
Inclusion criteria:
1. Women aged 18 to 75 years
2. Breast cancer diagnosis
3. Entering first cycle of chemotherapy
4. Performance status of 0–2 in the Eastern
Cooperative Oncology Group (ECOG) score
5. Subject must be willing and able to sign an
informed consent
Exclusion criteria:
1. History of renal (serum creatinine greater than 2.0
mg/ml) or hepatic insufficiency (bilirubin> 3.0 mg/dl
or serum albumin < 3.5 g/dl or prothrombin time <
60% in the absence of orally administered
anticoagulant therapy or ultrasound signs of
chronic liver damage)
2. History of heart failure
3. History of cardiac valvulopathy
4. Baseline LVEF < 50% determined by transthoracic
echocardiogram
5. Cardiogenic shock
6. Any serious medical comorbidity that determines
life expectancy as < 6 months
7. Current participation in any other clinical
investigation
8. Any condition that contraindicates chemotherapy
(i.e., pregnancy, lactation)
9. History of severe adverse reaction to carvedilol
10. History of severe adverse reaction to DHA
11. Previous treatment with β-blockers within the last
3 months
12. Use of vitamin E, vitamin C or probucol, during the
last 3 months
13. Use of orally administered anticoagulants
14. History of coagulation disorders
Enrollment and baseline phase assessments
Patients diagnosed with localized breast cancer at the
clinical campus are contacted by the study staff. After an
initial clinical evaluation and explanation of the study
protocol, patients agreeing to participate sign the in-
formed consent followed by undergoing a baseline
analysis including clinical evaluation and baseline labora-
tory and cardiovascular imaging to determine study eli-
gibility. Baseline analyses are performed at least 10 days
before the initial chemotherapy cycle, consisting of: (1)
general laboratory testing, including blood cell count,
INR/TTPA, full-biochemistry profile including serum
creatinine and electrolytes; (2) plasma levels of NT-
ProBNP and high-sensitivity cardiac troponin T (hs-
cTnT); (3) resting electrocardiogram; (4) transthoracic
echocardiogram; and (5) cardiac magnetic resonance.
Breast cancer patients meeting the inclusion criteria are
randomly allocated at a 1:1 ratio to either the interven-
tion (DHA and carvedilol) or the control (double-pla-
cebo) arms. Randomization will be computer generated
with homogeneous blocks of four by a specialist who is
not related to the research group. The same person also
assigns treatment and prepares the respective pillboxes
with ad-hoc labeling and perform monitoring adher-
ence. Patients, study staff, other care providers and data
analysts are blinded to group allocation. The acquisi-
tion of the echocardiographic images will be performed
by the same operator and will be reviewed by two other
independent operators.
Intervention
The study group is exposed to DHA at a dose of 1500
mg/day orally (preconditioning dose), starting 7 days be-
fore the beginning of the first chemotherapy cycle, and
carvedilol in a dose of 12.5 mg every 12 h orally (precon-
ditioning dose), starting 2 days before the chemotherapy
cycle. The daily doses of the preconditioning regimen
are delivered 7 days before the first cycle of chemother-
apy in a single, weekly, red pillbox with separate com-
partments per day. On the day of chemotherapy, after
the recovery of the red pillbox, the second weekly pill-
box (green) with separate compartments per day is deliv-
ered. Both preconditioning doses will last up to 2 days
after the initial cycle. From day 3 after the first chemo-
therapy cycle until the seventh day (green pillbox) the
doses of DHA and carvedilol will be reduced to 500 mg
per day and 6.25 mg every 12 h, respectively (mainten-
ance doses). Seven days after the first chemotherapy
cycle, the green pillbox is recovered and three transpar-
ent pillboxes with separate compartments per day are
delivered with maintenance doses. At the end of the 3
weeks, the transparent pillboxes are recovered and three
new white pillboxes are delivered with maintenance
doses. This reception and delivery of new pillboxes every
3 weeks is replicated until the end of the intervention.
The control arm group will likewise be exposed to
double placebo. This timing follows the standard breast
cancer adjuvant protocol used by the Chilean public
health system, based on four anthracycline cycles each,
separated by 21 days. The addition of trastuzumab or
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any other oncologic therapy during the standard adju-
vant protocol will not modify the intervention. The
pharmacological protocol will be discontinued in any pa-
tient who develops congestive heart failure or any other
adverse acute cardiac effect reverting to standard care
and will be unblinded. Other adverse events will be
monitored and reported during the trial in each clinical
evaluation by a team physician as well as in the usual
oncological controls by physicians who are not part
of the research team. Recommendations for Interven-
tional Trials (SPIRIT) checklist for this protocol is
also provided (Additional file 1). Generic carvedilol
and its placebos were purchased specifically for this
study. Natrol® DHA Super Strength and was supplied
free of charge by Nutrimarket Chile, a company not
participating in the study.
Follow-up protocol
Patients participate actively in this study for 6 months,
at which point the second CMR is performed. One year
after the first cycle of chemotherapy, a final phone con-
tact is to be carried out.
Follow up is performed and monitored by trained
study personnel who interview the patients by phone or
in person, including:
1. Clinical follow-up at 30, 90 and 180 days
2. General laboratory analyses: blood cell count and
full-biochemistry profile, including creatinine and
electrolytes, 2 and 4 days after the initial chemo-
therapy cycle
3. NT-ProBNP and hs-cTnT plasma levels (by ELISA)
2, 4 and 90 days after the first chemotherapy cycle
4. Oxidative stress parameters analysis at days 2, 4 and
90 after the first chemotherapy cycle
5. Resting electrocardiogram 2, 4 and 90 days after the
first chemotherapy cycle
6. Transthoracic echocardiogram at 90 and 180 days
after the chemotherapy cycle
7. CMR at 180 days after the initial chemotherapy
cycle
8. Final phone contact 1 year after the first
chemotherapy cycle
Study objectives – primary and secondary endpoints
The trial includes four co-primary endpoints to assess
the efficacy of the proposed strategy to inhibit or attenu-
ate the subclinical manifestations of anthracycline-
induced cardiotoxicity (AIC). The co-primary endpoints
include two imaging variables, a serum biomarker and
electrocardiographic variables. The first co-primary end-
point is changes in LVEF from baseline control to 180
days after the first chemotherapy cycle, determined by
CMR. The second co-primary endpoint is the percentage
of changes in global longitudinal strain (GLS) comparing
baseline with 90 and 180 days after the first cycle, deter-
mined by two-dimensional ECHO. The third co-primary
endpoint is the elevation in serum biomarkers, including
NT-ProBNP between baseline and 48 h after the first
chemotherapy cycle and/or elevations in levels of hs-
cTnT at 2, 4 and 90 days. The fourth co-primary end-
point is the prolongation in the corrected QT interval,
48 h after the first chemotherapy cycle.
Additionally, three secondary endpoints were included
to determine other imaging and clinical variables, as well
as to evaluate systemic biomarkers of oxidative stress.
The first secondary endpoint is the occurrence of major
adverse cardiac events during follow-up such as: cardiac
death, acute coronary syndrome, acute pulmonary
edema, clinical manifestations of heart failure and life-
threatening arrhythmias. The second secondary endpoint
is changes in LVEF from baseline compared to 90 and
180 days after the first chemotherapy cycle, determined
by two-dimensional ECHO. The third secondary end-
points are biomarkers of oxidative stress damage, as well
as parameters of intracellular and extracellular antioxi-
dant balance. In order to evaluate the oxidative stress
damage, plasma lipoperoxidation levels (malondialde-
hyde levels) will be measured at 2, 4 and 180 days after
the initial chemotherapy cycle. To evaluate antioxidant
balance, the Erythrocyte Thiol Index (GSH/GSSG) will
be determined at 2, 4 and 90 days after the first chemo-
therapy cycle. Given this is a pilot study, outcomes will
include the total number of patients screened, those eli-
gible, those providing informed consent and those com-
pleting the intervention treatment.
Timeline for participants
Figure 1 represents the patient timeline. Outlined in
Fig. 2 is the study schedule of enrollment and assess-
ments (Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT Figure).
Sample size and data analysis
The sample size was estimated on the basis of results
from our previous protocol (63), where the carvedilol-
supplemented group showed a 51% reduction of differ-
ential LVEF (ΔLVEF) compared with the placebo group.
ΔLVEF was determined between the last follow-up
ECHO at approximately 1 year (10–12months) with re-
spect to baseline ECHO, both performed by two-
dimensional evaluation. Assuming normal distribution
and a common relative standard deviation of 48% (sup-
plemented group), with 5% two-sided significance, a
sample size of 32 will be required to provide 80% statis-
tical power to detect a 12.5% ΔLVEF reduction assessed
by CMR to provide greater precision.
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Results will be analyzed according to intention-to-treat
criteria, including all randomized patients who are able
to initiate intervention, independent of treatment and
follow-up period durations. Continuous variables will be
expressed as means ± standard deviation or medians and
interquartile ranges depending on their distribution. Distri-
bution will be analyzed using the Kolmogorov-Smirnov
test. Student’s T test and Pearson correlation analyses
will be applied for normally distributed continuous vari-
ables. The Mann-Whitney U test and Spearman’s correl-
ation will be used for non-normally distributed continuous
variables. Categorical variables will be expressed as num-
bers and frequencies (%). Differences between the frequen-
cies will be performed by the chi-square test or by Fisher’s
Fig. 1 Timeline of the Carvedilol-DHA (CarDHA) trial. hs-cTnT high-sensitivity cardiac troponin T, NT-ProBNP NT-proB-type natriuretic peptide, EKG
resting electrocardiogram, ECHO echocardiography, CMR cardiac magnetic resonance, DHA docosahexaenoic acid
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
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Final phone 
contact X
Fig. 2 Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) Figure (required for study protocols). CMR cardiac magnetic
resonance, DHA docosahexaenoic acid, ECHO echocardiography, hs-cTnT high-sensitivity cardiac troponin T, NT-ProBNP NT-proB-type natriuretic
peptide, EKG resting electrocardiogram
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exact test. Multiple linear regression analysis will be used to
assess independent predictors of the absolute semiannual
changes in ΔLVEF, to identify factors associated with
ΔLVEF. The difference between the groups will be consid-
ered significant with a p value of < 0.05.
Discussion
CarDHA is a limited, academic, randomized, placebo-
controlled, double-blind, two-arm clinical trial designed
to evaluate the efficacy of the proposed strategy to in-
hibit or attenuate subclinical manifestations of
anthracycline-induced cardiotoxicity (AIC).
The four co-primary endpoints of the study are: (1)
changes in LVEF as evidenced by CMR; (2) changes in
global longitudinal strain (GLS) manifested in echocar-
diographic imaging; (3) elevations in levels of serum bio-
markers (NT-ProBNP/hs-cTnT); and (4) QT interval
prolongation by electrocardiographic evaluation.
Unlike similar AIC primary prevention protocols based
on carvedilol alone, to our knowledge this trial is the
first cardio-oncology study to: (1) be expressly designed
as a therapeutic strategy focusing on attenuating the
oxidative stress associated to AIC, rather than on the β-
blocking effects of carvedilol; and (2) attempt to evaluate
the potential cardioprotective effects of a dual strategy
(comprising non-ischemic cardiac preconditioning
through endogenous antioxidant capacity enhance-
ment through DHA, plus the direct antioxidant
properties of carvedilol, in a sequential regimen spe-
cifically designed to attenuate chemotherapy-induced
oxidative stress). We expect the inhibition or attenu-
ation of the anthracycline-derived oxidative heart
injury generated by two unrelated antioxidant path-
ways will be more efficient than the potential of
one the pathways alone.
The main limitations of our study are the small sample
size, the non-use of consensus criterion (post-chemo-
therapy LVEF decline ≥ 10% to < 50%) to define a cardi-
otoxic event for the first co-primary endpoint [6] and to
have a single-center trial. The use of CMR imaging to
evaluate our first co-primary endpoints, the gold-
standard method to evaluate LVEF decline, partially
compensates the first two limitations, since we are not
limited by echocardiographic sensitivity and should be
able to detect subclinical cardiotoxicity at the early
stages [10]. Additionally, although most cardio-oncology
trials have used the ≥ 10% consensus criterion to estab-
lish cardiotoxicity, that range was defined arbitrarily as a
criterion for two reasons: first, it is widely used as cut-
off point to evaluate the continuity of oncological treat-
ment; and second, it reflects the echocardiographic sen-
sitivity limits to establish a decline in LVEF with
certainty [10]. A smaller than 10% in AIC-induced LVEF
reduction does not imply the absence of cardiotoxicity.
Thus, other clinical trials with relatively small sample
sizes using CMR to evaluate LVSD as the primary end-
point, such as the PRADA and MANTICORE trials, also
rule out the criterion of a LVEF decline ≥ 10% for event
definition, in favor of comparing mean differences be-
tween the groups [61, 62]. Moreover, limiting the de-
scription of a cardiotoxic event to a consensus definition
of decline in LVEF can underestimate the manifestation
of other types of cardiotoxicity (such as an elevation in
cardiac biomarkers), some of which could be associated
with the future development of later clinical manifesta-
tions [63, 64]. Regarding the lack of representative-
ness associated with single-center studies, the San
Juan de Dios is a public hospital that provide health-
care to a large urban population, and several rural
surrounding locations. It also has the advantage that
all echocardiographic images will be performed by the
same person, and analyzed by the same two specialist.
Additionally, it plays in our favor the fact that in
Chile the doxorubicin protocol for localized breast
cancer is standardized in all public hospitals and is
quite similar among private health services.
The relative short follow-up time (6 months) could also
be considered a problem in this study. Nevertheless, Cardi-
nale et al. previously reported in a large prospective study,
including 2625 patients, an early LVEF drop in patients de-
veloping cardiotoxicity [6]. In that study the median time
elapsed between the end of chemotherapy and cardiotoxi-
city development was 3.5months. Therefore, it sems to be
difficult not to find differences at 6 months through CMR.
Finally, for some authors, the use of a combination therapy
could also be considered a limitation [35]. This implies a
difficulty when comparing our results to similar studies
based on carvedilol alone. Our design also difficult estimat-
ing attributable fraction to carvedilol if we find beneficial ef-
fects. Notwithstanding, we maintain that beyond the use of
CMR, the greatest contribution of this protocol is to evalu-
ate a prophylactic strategy completely designed to attenuate
the oxidative stress derived from AIC, with the inclusion of
two different antioxidant strategies administered sequen-
tially to enhance the effects.
In conclusion, CarDHA is the first randomized trial
designed to evaluate the potential cardioprotective ef-
fects of a dual antioxidant strategy comprising a non-
ischemic pharmacologic cardiac preconditioning based
on DHA and carvedilol, specifically designed to attenu-
ate oxidative stress as a key factor in AIC development
and progression. Potentially favorable results of this
study will generate the basis for larger clinical trials to
further explore the efficacy of this innovative strategy.
Trial status
The protocol was reviewed and approved by the Institu-
tional Review Board of the San Juan de Dios Hospital
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and the Ethics Committee of the University of Chile,
whose medical school is associated with San Juan de
Dios Hospital, as only the university has a committee
accredited by the Chilean Ministry of Health.
Enrollment was started on 30 May 2016. However, the
first patient entered into the study on 10 August 2016.
As of 26 October 2018, the study had enrolled 30 pa-
tients at the San Juan de Dios Hospital. The study is be-
ing conducted in accordance with “Good Clinical
Practice” recommendations, based on the Declaration of
Helsinki (2002). The trial has been registered at the
ISRCTN registry with the code ISRCTN69560410 ap-
plied on 8 June 2016. A flow chart of this study is pre-
sented in Fig. 3.
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